Holen Sie sich die Stockscreener-App
20.91
3.62%
0.73
Handel nachbörslich:
20.91
Schlusskurs vom Vortag:
$20.18
Offen:
$20.02
24-Stunden-Volumen:
305.68K
Relative Volume:
0.53
Marktkapitalisierung:
$889.47M
Einnahmen:
$720.53M
Nettoeinkommen (Verlust:
$79.23M
KGV:
12.56
EPS:
1.6648
Netto-Cashflow:
$132.94M
1W Leistung:
+0.63%
1M Leistung:
+11.19%
6M Leistung:
-26.63%
1J Leistung:
-30.78%
1-Tages-Spanne:
$19.89
$21.07
1-Wochen-Bereich:
$19.55
$21.07
52-Wochen-Spanne:
$16.64
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
20.91 | 849.91M | 720.53M | 79.23M | 132.94M | 1.6648 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 3.6% Rally? GF Value Says Undervalued - GuruFocus
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals - simplywall.st
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7, - GuruFocus
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - marketbeat.com
Amphastar director Richard Prins disposes of shares valued at $161,851 By Investing.com - Investing.com South Africa
Amphastar director Richard Prins disposes of shares valued at $161,851 - Investing.com
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30 - Stock Titan
Amphastar CFO William Peters sells $183,886 in company stock - Investing.com
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares - marketbeat.com
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade - Stock Titan
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts - marketbeat.com
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning - TradingView
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap - Sahm
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating - marketbeat.com
Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler - marketbeat.com
Wells Fargo & Company Increases Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $20.00 - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Strong Earnings - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Amphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026 - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains - Stock Titan
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - Arizona Daily Star
Pacer Advisors Inc. Buys 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
What To Expect From Amphastar Pharmaceuticals’s (AMPH) Q2 Earnings - The Globe and Mail
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook Reveals 8.80% Upside Potential - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Has $6.37 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 - TradingView
Amphastar Pharmaceuticals Inc (AMPH) Cash Flow - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence - TradingKey
Rice Hall James & Associates LLC Increases Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
AMPH|Amphastar Pharmaceuticals Inc|Price:19.180|Chg%:+0.460 - TradingKey
Amphastar Pharmaceuticals Inc - TradingKey
AMPH|Amphastar Pharmaceuticals Inc|Price:18.720|Chg%:-0.150 - TradingKey
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Amphastar Pharmaceuticals Inc (AMPH) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts - Yahoo! Finance Canada
Amphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
5.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):